TTIPF (Thiogenesis Therapeutics) Beginning Cash Position: $1.18 Mil (As of Mar. 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Beginning Cash Position?

Thiogenesis Therapeutics TTIPF -6.67% 12 Beginning Cash Position is $1.18 Mil as of Mar. 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Thiogenesis Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $1.18 Mil.

Thiogenesis Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($4.09 Mil) to Dec. 2025 ($2.54 Mil) and declined from Dec. 2025 ($2.54 Mil) to Mar. 2026 ($1.18 Mil).

Thiogenesis Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($4.62 Mil) to Dec. 2024 ($4.97 Mil) but then declined from Dec. 2024 ($4.97 Mil) to Dec. 2025 ($2.79 Mil).

Thiogenesis Therapeutics Beginning Cash Position Related Terms

Thiogenesis Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics Beginning Cash Position Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.14 0.12 4.62 4.97 2.79

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 2.20 4.09 2.54 1.18
TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $1.18 Mil mean?
Thiogenesis Therapeutics (TTIPF) has a Beginning Cash Position of $1.18 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Thiogenesis Therapeutics and its competitors.
Is Thiogenesis Therapeutics' Beginning Cash Position too high?
Thiogenesis Therapeutics' current Beginning Cash Position is $1.18 Mil. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Beginning Cash Position compare to VRTX and REGN?
Thiogenesis Therapeutics' Beginning Cash Position of $1.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current Beginning Cash Position is $1.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current Beginning Cash Position of $1.18 Mil. The current Beginning Cash Position is $1.18 Mil. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current Beginning Cash Position is $1.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price